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ABSTRACT
Introduction: During the past few decades, the number of diseases identified to be 
caused by chromosomal microdeletions has increased quickly, bringing a new and 
crucial role for cytogenetics on the diagnosis of these conditions. The purpose of this 
study was to identify and characterize chromosomal microdeletions associated with 
malformation syndromes and intellectual disability.
Methods: We retrospectively evaluated a consecutive series of samples from a cohort 
of 598 subjects with clinical symptoms of a microdeletion syndrome, including the 
deletion of chromosomes 4p16.3, 5p15.2, 5q35, 7q11.23, 8q24.12, 15q11.2, 16p13.3, 
17p13.3, 17p11.2,2, and 22q11.2, as investigated by fluorescence in situ hybridization 
(FISH). Array-based comparative genomic hybridization (array-CGH) was performed 
on 25 samples with microdeletions.
Results: A total of 598 samples were evaluated from patients whose clinical phenotypes 
were most indicative of 22q11.2 deletion syndrome (29.10%), Prader-Willi syndrome 
(23.41%), Angelman syndrome (16.89%), and Williams-Beuren syndrome (14.72%). In 
142 of the samples (23.75%), a chromosomal imbalance associated with phenotypic 
abnormalities was found. The deletion of  7q11.23 was the most frequent (8.03%), 
followed by del22q11.2 (5.68%) and del15q11.2 (5%).
Conclusion: Our study reinforces the idea that the effort to improve the capacity 
to perform molecular cytogenetic investigations associated with a qualified clinical 
evaluation is crucial for the detection and precise characterization of submicroscopic 
chromosome deletions, bringing benefits to patients, relatives, and genetic counselors. 
It also contributes to the continuing education of cytogeneticists and to the knowledge 
of chromosomal rearrangements associated with genomic disorders.
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The phenotypic spectrum observed in some disorders can be attributed 
to the segmental aneuploidy (deletion, duplication, disruption, or point 
mutation) of a single dosage-sensitive gene. The lack of a protein encoded 
by one allele of a gene with a corresponding reduction in the amount of the 
protein to approximately 50% is called haploinsufficiency if a decreased level 
of the protein is insufficient to sustain its normal function, thus leading to an 
abnormal phenotype. The clinical outcomes of the well-known microdeletion 
syndromes, which are a consequence of submicroscopic chromosomal 
deletions that lead to haploinsufficiency, are relatively specific. The phenotypic 
characteristics are often recognized before the causal microdeletions are 
identified1. In 1986, Schmikel2 proposed the term “contiguous gene” for a 
group of disorders characterized by microdeletions or microduplications of 
chromosomal segments associated with clusters of single gene disorders. In 
contrast to single gene disorders, these conditions, especially those including 
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developmental delay or intellectual disability and 
congenital developmental abnormalities, result 
from submicroscopic chromosomal rearrangements 
encompassing several genes, with at least two of 
them being dosage-sensitive but, overall, functionally 
unrelated to each other3.
In such contiguous gene deletions (e.g., Williams-
Beuren syndrome [WBS], Prader-Willi syndrome 
[PWS], Angelman syndrome [AS], and 22q11.2 
deletion syndrome [22qDS], the phenotype of the 
disorder results from an inappropriate dosage of 
only the dosage-sensitive genes located within the 
rearranged genomic region. In the past 15 years, 
technological advances, such as array-based 
comparative genomic hybridization (array-CGH)4,5, 
have enabled the detection of intermediate-size 
rearrangements (> 1,000 base pairs but typically 
less than 5 megabase pairs [Mb] in length) resulting 
in a previously unrecognized large-scale form of 
structural genomic variation known as copy-number 
variation6,7. The most common mechanism of conveying 
a phenotype by microdeletion or microduplication 
is altering the copy number of a dosage-sensitive 
gene(s) located within the rearranged region8,9.
Improvements in classical and molecular cytogenetic 
techniques over the past 40 years have allowed for 
the increasingly sensitive detection of chromosomal 
rearrangements, including deletions and duplications 
related to genomic disorders10. Fluorescence in situ 
hybridization (FISH) was introduced in the late 1980s11 
and can readily detect submicroscopic chromosomal 
rearrangements that involve regions smaller than 3 
Mb. This powerful technique with broad applications 
in cytogenetics laboratories still has enormous value 
for retrospective diagnosis and physical mapping 
of chromosomal rearrangements using cells in 
suspension stored in a biorepository.
The purpose of this study was to identify and 
characterize chromosomal microdeletions associated 
with malformation syndromes and intellectual disability 




This retrospective study included cases referred for 
investigation at the molecular cytogenetics laboratory 
at the Hospital de Clinicas de Porto Alegre, state 
of Rio Grande do Sul, Brazil from 1998 to 2013. 
During this 15-year period, a total of 1,128 samples 
were referred for molecular cytogenetic analysis. 
Of these, 745 cases had a clinical diagnosis of a 
microdeletion syndrome. From these, 598 cases 
were included in the present study, as 147 cases 
did not have available medical records or did not 
have samples available for investigation with FISH. 
From the total of selected cases, 93.5% had been 
previously analyzed by a karyotype of peripheral blood 
lymphocytes using the Giemsa banding technique 
and the nomenclature developed by the International 
System for Human Cytogenetic Nomenclature12. 
The results of previous cytogenetic analyses were 
obtained for almost all cases, except for those in which 
no karyotype was available at the time of selection. 
To be included in the study, the subjects needed to 
have clinical symptoms of a specific chromosomal 
microdeletion3. Cases that had only a suspected 
non-specified clinical microdeletion, cases without 
medical records, and cases whose samples were not 
available for investigation by FISH were excluded. 
Information regarding the cases was retrieved from 
multiple hospital records, and final cytogenetic and 
clinical reports were reviewed.
Fluorescence in situ hybridization
FISH experiments were carried out by standard 
techniques in all cases using commercially available 
locus-specific probes (Abbott Laboratories, Des 
Planes, Illinois, EUA and Cytocell – Cambridge) 
for the following regions: 4p16.3 (WHSCR); 5p15.2 
(D5S23, D5S721); 5q35 (NSD1); 7q11.2 (ELN/LIMK1/
D7S613); 8q23.3 (TRPS1) and 8q24.11-8q24.12 
(EXT1); 15q11-q13 (SNRPN); 16p13.3 (CREBBP); 
17p13.3 (LSI1); 17p11.2 (RAI1) and 22q11.2 (TUPLE1). 
Hybridizations were analyzed with an epifluorescence 
microscope, and images were captured with a 
charged-couple device camera. At least 30 cells 
were analyzed per hybridization. We considered a 
chromosome region deleted when the FISH signal 
from the corresponding probe was absent from one 
of the homologous chromosomes.
Chromosomal microarray analysis
To validate the use of microarrays for diagnostic 
purposes at our laboratory and to better define some 
of the chromosomal rearrangements detected by 
the FISH analysis, the critical regions of 25 DNA 
samples, twelve with del4p16.3, nine with del5p15.2, 
two with del8q24.12, one with del17p13.3, and 
one with del22q11.2, were further mapped. Whole-
genome array-CGH was performed using a 60-mer 
oligonucleotide-based microarray with a theoretical 
resolution of 40 kb (8 × 60K, Agilent Technologies 
Inc., Santa Clara, CA). Labelling and hybridization 
were performed following the standard protocols 
provided by Agilent, version 2011. The arrays were 
analyzed by the microarray scanner (G2600D) and the 
Feature Extraction software (v9.5.1) (both from Agilent 
Technologies). Imaging analyses were performed 
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using Cytogenomics v2.0 and Cytogenomics v2.7 
with the statistical algorithm ADM-2 and a sensitivity 
threshold of 6.0.
Ethics review
This study was approved by the Research Ethics 
Committee of Hospital de Clínicas de Porto Alegre 
(HCPA) with number GPPG 10-560 and was conducted 
in accordance with all current ethical rules13.
RESULTS
From the 598 subjects included in the final sample, 
301 (50.33%) were female and 297 (49.67%) were 
male. The age range of the individuals at the moment 
of FISH analysis varied from 1 day to 49 years 
(mean 8.2 years; standard deviation 4.0 years). The 
majority of the subjects originated from the state of 
Rio Grande do Sul (94%), and 57% of these were 
from small countryside towns. The most relevant 
clinical features of the patients were collected from 
multiple hospital records (table 1).
The most common conditions suspected on clinical 
grounds were 22qDS (29.10%), PWS (23.41%), AS 
(16.89%), and WBS (14.72%), followed by Wolf-
Hirschhorn syndrome (WHS) (3.34%), Cri-du-Chat 
syndrome (CdCS) (2.51%), Miller-Diecker syndrome 
(MDS) (2.51%), Sotos syndrome (SoS) (2.34%), 
Rubinstein-Taybi syndrome (RTS) (2.17%), Smith-
Magenis syndrome (SMS) (1.67%), and Langer-
Giedion syndrome (LGS) (1.34%) (table 2).
Of the 598 cases included in our study, conventional 
cytogenetic examinations (from peripheral blood) were 
performed in 559 (93.48%) of them, and abnormalities 
were observed in 22 (3.93%) of them (table 1). The 
deletion of chromosomes 5p15.2 (CdCS) and 4p16.3 
(WHS) were the most common abnormalities detected 
through the karyotype. Abnormal karyotypes in 
patients with LGS (del8q24.12), 22qDS (del22q11.2), 
and MDS (del17p13.3) were also reported. For 39 
(6.52%) patients, the result of the karyotype was 
not available.
A deletion of 7q11.23 was detected in 8.03% of 
the 598 samples, followed by the del22q11.2 (5.68%), 
del15q11.2 (5%), del4p16.3 (2.67%), del5p15.2 
(1.50%), del17p13.3 (0.33%), del8q24.12 (0.33%), 
and del17p11.2 (0.17%) (figure 1). FISH investigations 
were normal for all the samples of patients with SoS 
and RTS (table 2).
Considering each group of samples separately, 
FISH analysis identified the del4p16.3 abnormality 
in 16/20 (80%) of WHS samples, the del5p11.2 in 
9/15 (60%) of CdCS samples, the del7q11.23 in 
48/88 (54.54%) of WBS samples, the del8q24.12 in 
2/8 (25%) of LGS samples, the del15q11.2 in 13/101 
(12.87%) of AS samples and in 17/140 (12.14%) of 
PWS samples, the del17p13.3 in 2/15 (13.33%) of 
MDS samples, the del17p11.2 in 1/10 (10%) of SMS 
samples, and the del22q11.2 in 34/174 (19.54%) of 
the 22qDS samples (table 2).
To establish the microarray methodology for 
diagnostic purposes in our laboratory, array-CGH 
analysis of fifteen samples with del4p16.3, nine 
samples with del5p15.2, and one sample with 
del8q24.12 was performed. The aim was to determine 
the approximate size of the deleted region and to 
map the critical region. In the twelve DNA samples 
where del4p16.3 was confirmed by FISH, eleven 
showed a terminal 4p deletion between 3.7 and 14.7 
Mb, and one showed an 11 Mb interstitial deletion. 
The nine 5p15.2 classical terminal deletions were 
between 11.2 and 18.4 Mb. The DNA sample from 
the patient with LGS showed a single copy loss of 
the long arm of chromosome 8 of 6.43 Mb in size14. 
The map position is based on the UCSC Genome 
Browser, Feb. 2009, gh19 (NCBI Build GRCH37 
reference sequence) (figure 2).
This study showed an increase in the number of 
cases investigated by FISH in all periods of diagnosis: 
75 cases from 1998 to 2003, 174 cases from 2004 
to 2008, and 349 cases from 2009 to 2013 (table 3).
DISCUSSION
Microdeletion syndromes are rare clinical entities 
caused by chromosomal deletions at or below the 
level of detection by classical banded cytogenetic 
studies. These cases may include the sequelae of 
haploinsufficiency of two or more dominant genes in 
close proximity (“contiguous gene syndromes”). The 
characterization of clinically recognizable syndromes 
can be achieved through a number of cytogenetic 
and molecular approaches. In Brazil, cytogenetics 
plays an important role in the diagnosis of these 
rare diseases. The most commonly used method to 
demonstrate the occurrence of a deletion in diagnostic 
laboratories is still FISH with cloned segments present 
within the deleted segment, followed by multiplex 
ligation-dependent probe amplification (MLPA) analysis 
using markers within the critical segments. The main 
drawbacks of FISH are its failure to detect small 
deletions and duplications as well as the fact that 
it is easily affected by the quality of the metaphase 
spreads. MLPA is less time-consuming and capable of 
detecting smaller, atypical deletions and duplications 
in microdeletion syndromes. Compared to FISH, 
MLPA is also a low cost and technically uncomplicated 
method for the study of microdeletions, making it 
a good alternative for many routine applications15. 
However, for retrospective studies where only cells in 
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Table 1: Demographic, clinical and standard cytogenetic data obtained from subjects with clinical suspicion of a 
microdeletion syndrome.
Syndrome OMIM Age 
range
M F Most frequent clinical 





AS 105830 1y-28y 43 58 DD/ID, ataxic gait, 
inappropriately happy 
disposition, hypotonia, 
microcephaly, severe speech 
impairment, seizures
101 - - 101
CdCS 123450 4m-35y 7 8 High-pitched monotonous cry, 
microcephaly, hypertelorism, 
epicanthic folds, round face, 
severe DD and learning 
disabilities
6 9 - 15
LGS 190351 4m-20y 5 3 Long flat philtrum, ID, 
exostosis, cone-shaped 
epiphyses
7 1 - 8
22qDS 188400
192430
NB- 40y 88 86 Congenital heart defects/ 
conotruncal and aortic arch, 
facial dysmorphic features, 
DD
152 2 20 174
MDS 247200 2m-30y 10 5 Microcephaly, growth 
retardation, DD/ID with 
seizures and EEG 
abnormalities
14 1 - 15
PWS 176270 3m-43y 68 72 ID, postnatal hipotonia, 
obesity due to food 
seeking, hypogonadotropic 
hypogonadism
127 1 12 140
RTS 180849 1y-49y 8 5 ID, broad thumbs and toes, 
facial dysmorphism
13 - - 13
SoS 606681 NB-17y 7 7 DD, increased birth length 
and weight, excessive growth 
in childhood
9 - 5 14
WBS 194050 1m-39y 48 40 DD/ID, overfriendliness, 
congenital heart disease, 
specially SVAS, facial 
characteristics including 
bulbous nasal tip, wide mouth, 
full lips, full cheeks, and small 
widely spaced teeth
88 - - 88
WHS 194190 NB-39y 8 12 A “Greek-helmet” profile, low 
birth weight and postnatal 
failure to thrive, microcephaly, 
DD
10 8 2 20
SMS 182290 3y-19y 5 5 DD, learning disability, 
behavioral disturbance, facial 
characteristics
10 - - 10












AS: Angelman syndrome; CdCS: Cri-du-Chat syndrome; LGS: Langer Giedion syndrome; 22qDS, 22q11.2 deletion syndrome; MDS: Miller-
Diecker syndrome; PWS: Prader-Willi syndrome; RTS: Rubinstein-Taybi syndrome; SoS: Sotos syndrome; WBS: Williams-Beuren syndrome; 
WHS: Wolf-Hirschhorn syndrome; SMS: Smith-Magenis syndrome; OMIM: Online Mendelian Inheritance in man; NB: newborn; m: months; 
y: years; DD: developmental delay; EEG: electroencephalogram; ID: intellectual disability; SVAS: supravalvular aortic stenosis; M: male; F: 
female; NA: not available; N: normal; A: abnormal; n: total.
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Table 2: FISH findings in 598 cases with a suspicion of microdeletion associated with the clinical diagnosis.
Locus Syndrome Total Non-deleted Deleted
4p16.3 Wolf-Hirschhorn 20 4 16
5p15.2 Cri-du-Chat 15 6 9
5q35 Sotos 14 14 -
7q11.23 Williams-Beuren 88 40 48
8q24.12 Langer-Giedion 8 6 2
15q11.2 Angelman 101 88 13
15q11.2 Prader-Willi 140 123 17
16p13.3 Rubinstein-Taybi 13 13 -
17p13.3 Miller-Diecker 15 13 2
17p11.2 Smith-Magenis 10 9 1
22q11.2 22q11.2 deletion 174 140 34
Total (%) All syndromes 598 456 142
Figure 1: FISH results with locus-specific probes for the microdeletions investigated in this study. Partial metaphases. A: 
Wolf-Hirschhorn critical region probe. The absence of the red signal on one copy of chromosome 4 (2.67% of the cases) 
indicates the deletion of the critical region. B: Cri-Du-Chat critical region. The absence of the green/red signal on one 
copy of chromosome 5p (1.5% of the cases) indicates deletion of the critical region. C: Elastin gene probe. The absence 
of the red signal on one copy of chromosome 7 (8.03% of the cases) indicates 7q11.23 deletion. D: Langer-Giedion 
syndrome region probe. The blue 8p11-q11 region (control), the red 8q23.3/TRPS1 region, and the green 8q24.1/EXT1 
region are shown. The absence of the red and green signals on one copy of chromosome 8 (0.33% of the cases) indicates 
deletion of both genes. E: Prader-Willi/Angelman region probe. The absence of the red signal (5% of the cases) indicates 
the deletion of the SNRPN region. F: LIS1 probe. There is a lack of red signal in a patient with Miller-Dieker syndrome 
(0.33% of the cases). G: Smith Magenis region probe. There is a lack of red signal (0.17% of the cases), indicating the 
deletion of the critical region. H: 22q11.2 deletion syndrome region probe. The absence of the red signal (5.68% of the 
cases) indicates deletion of the critical region. A, F, G: probes from Abbott Molecular Inc., Des Plaines, IL; B, C, D, E, H: 
probes from Cytocell, Cytocell Ltd., Cambridge, UK. FISH: fluorescence in situ hybridization; TRPS: trichorhinophalangeal 
syndrome; EXT: exostosin; SNRPN: small nuclear ribonucleoprotein polypeptide N; LIS: lissencephaly.
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Figure 2: Array-CGH ratio profiles of the chromosomes in five cases with microdeletions using genomic DNA from the 
patients as test (in red) and DNA from normal subjects as reference (in blue). The test/reference ratio data for each 
chromosome are shown. Each dot represents a single probe (oligo) spotted on the array. The log ratio of the chromosome 
probes is plotted as a function of chromosomal position. Copy number loss shifts the ratio to the left (value of about –1x). 
The ideogram of each chromosome (left margin) shows the location of each probe. The probe log2 ratios were plotted 
according to genomic coordinates (based on the UCSC Genome Browser, February 2009, NCBI Build 37 reference 
sequence). A: A ~3.7 Mb terminal deletion at chromosome 4p16.3 (red area). B: A ~11.2 Mb terminal deletion at 
chromosome 5p15.33-p15.2 (red area). C: A ~ 5.2 Mb interstitial deletion at chromosome 8q23.3-q24.12 (red area). 
Array-CGH: array-based comparative genomic hybridization.
Table 3: Samples investigated considering the chromosome critical region according to the period that FISH analysis 
was performed.
Locus 1998-2003 2004-2008 2009-2013 Total (%)
4p16.3 2 4 14 20 (3.34)
5p15.2 - 3 12 15 (2.51)
5q35 - 4 10 14 (2.34)
7q11.23 18 22 48 88 (14.72)
8q24.12 - 5 3 8 (1.34)
15q11.2 21 63 157 241 (40.30)
16p13.3 - 7 6 13 (2.17)
17p13.3 - 10 5 15 (2.51)
17p11.2 - 4 6 10 (1.67)
22q11.2 34 52 88 174 (29.10)
Total (%) 75 (12.54) 174 (29) 349 (58.36) 598 (100)
suspension are available and no DNA samples can 
be obtained from most patients, as in our study, FISH 
analysis is an alternative method for the identification 
of submicroscopic chromosomal deletions.
The deletions of chromosomes 5p15.2 (CdCS) and 
4p16.3 (WHS) were the most common abnormalities 
detected by chromosome analysis in our samples. 
This result was expected because these classical 
deletions can be easily detected in good quality 
metaphase chromosomes. With the exception of one 
case of del8q24.12 and one case of del17p13.3, none 
of the other microdeletions were detected through a 
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standard karyotype. Although some microdeletions, 
such as del8q24.12, del15q11.2, del17p13.3, and 
del22q11.2, can potentially be detected through 
a high-resolution karyotype, the majority will not 
be confidently recognized using only conventional 
cytogenetic techniques unless, of course, they occur 
as unbalanced translocations.
In our study, 598 samples were evaluated by 
FISH, and 142 (23.75%) of them were found to 
have chromosomal imbalances related to the clinical 
diagnosis of the subjects. Although among the suspected 
clinical diagnosis the most common conditions were 
22qDS (29.10%), PWS (23.41%), AS (16.89%), and 
WBS (14.72%), del7q11.23 was the most frequent 
abnormality detected by FISH analysis (8.03%), 
followed by del22q11.2 (5.68%) and del15q11.2 (5%). 
The overall frequency of microdeletion syndromes in 
the Brazilian population remains unknown, making 
comparative studies difficult. The differences between 
similar studies can also be explained, in part, by the 
diversity of the samples, the selected criteria, and 
the methodologies employed16.
The fact that the 22qDS, also known as DiGeorge or 
Velocardiofacial syndrome, corresponded to the most 
common deletion detected by molecular cytogenetic 
investigation was not surprise. It is estimated that 
between two and ten out of every 1,000 live births 
are affected by some type of cardiac malformation16,17, 
and some congenital heart diseases are associated 
with the clinical symptoms resulting from del22q112. 
Speaking of which, del22q11.2 is one of the most 
common human genetic microdeletions, and the 
affected individuals have a great probability of 
undergoing medical interventions and hospitalization 
throughout their lives.
Nevertheless, FISH has limitations in the detection 
of microdeletions. Occasionally, patients with small and 
unusual deletions may escape detection, depending 
on the specificity of the fluorescent probe. In addition, 
the cases with gene mutations or imprinting mutations 
that occur in some microdeletion syndromes like AS, 
PWS, SoS, MDS, SMS and RTS cannot be detected 
by FISH. This limitation should be considered when 
observing that we did not detect any microdeletion 
among the SoS and RTS cases. We are concerned 
that some of the cases may still be misdiagnosed. 
We assume that this study likely failed to detect 
some microdeletions due to the reduced number 
of cases in specific groups of subjects and/or due 
to an incorrect clinical diagnosis. We should also 
consider that smaller rearrangements in the critical 
regions in some of our cases were potentially not 
detected with probes used by FISH. Thus, even if the 
FISH analysis was normal, the clinical diagnosis of 
a microdeletion syndrome should not be excluded.
Until relatively recently, high-resolution G-banded 
karyotyping and FISH studies using probes targeted 
to known microdeletion loci were considered the gold 
standard for detecting cytogenetic aberrations18. These 
testing strategies have been strongly challenged by 
the development of array-CGH, which enables the 
simultaneous testing of multiple loci for copy number 
differences. Furthermore, array-CGH has a much higher 
sensitivity compared to high-resolution karyotyping 
and can target more loci than FISH in a cost-effective 
manner, in addition to being more successful than 
FISH and MLPA in the detection of small chromosomal 
duplications and atypical microdeletions.
To validate the use of array-CGH methodology in 
our laboratory for diagnostic purposes and to determine 
the deletions sizes in some cases, we mapped the 
critical regions in 25 cases of microdeletions previously 
detected by FISH. Fifteen samples with del4p16.3, 
nine samples with del5p15.2, and one sample with 
del8q24.12 were analyzed. Array-CGH analysis 
provided a better delineation and more precise mapping 
of chromosomal deletions compared with FISH. It 
can be proposed that both methods, used together, 
are extremely valuable tools for the diagnosis and 
study of chromosomal rearrangements and that the 
implementation of both techniques are imperative for 
the cytogenetic laboratories that provide diagnoses 
to the Brazilian public health system (Sistema Único 
de Saúde, SUS). However, the adoption of these 
methodologies is economically questionable in the 
context of the SUS medical system.
The clinical evaluation of subjects with microdeletions 
continues to challenge clinicians and requires a high 
degree of experience and expertise. Although some 
steps in finding the diagnosis are highly standardized 
(for example, database searches, clinical utility 
gene cards, and standard clinical scores), others 
are not suitable for standardization. The diagnosis 
of microdeletion syndromes based only on clinical 
assessment may be difficult because of the great 
variability of the manifestations of symptoms, especially 
relative to the size of the deletion and the expertise 
of the clinical geneticist19.
Our study found an upward trend in the number 
of microdeletion diagnoses in recent years. More 
than half (58%) of microdeletions were identified 
between 2009 and 2013, which coincided with the 
efforts to establish new methods and improve the 
capacity to study chromosomal abnormalities in our 
hospital (table 3). Although the number of cases in 
our study was small for some microdeletions, we 
observed a significant increase in the number of 
cases according to the period of the cytogenetic 
diagnosis. This result likely reflects, among other 
factors, improved knowledge and practical skills 
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obtained through the years regarding the capacity 
of pediatricians and clinical geneticists to clinically 
recognize such disorders.
The confirmation of a clinical diagnosis of microdeletion 
syndromes is crucial for the clinical follow-up of the 
patients and the genetic counseling of the family. The 
challenge to the FISH approach is that the examination 
must be sufficiently indicative of a particular syndrome 
for the geneticist to know exactly which region(s) 
and/or chromosome(s) to investigate. There are also 
syndromes that do not become distinct until a certain 
age when a particular behavior or clinical manifestation 
presents. Array-CGH allows professionals to detect 
chromosomal abnormalities consistent with a genetic 
syndrome at an earlier age when only a few clinical 
findings are clear19.
Currently, cytogenetic testing in developed countries 
is likely to use mostly array-CGH technology for the 
diagnosis of genomic disorders18. As the number of 
recognized genetic syndromes and chromosome 
abnormalities grows, and, because the clinical 
characteristics of those syndromes overlap, it 
becomes more difficult from a clinical examination 
alone to infer exactly which syndrome is affecting 
an individual19. However, the high cost associated 
with the cytogenetic molecular methods and the 
lack of technical skills and professional experience 
needed for their application are major challenges for 
developing countries such as Brazil.
Medical management can be greatly impacted 
by an early diagnosis. Furthermore, it helps patients 
and their families to understand their disability. Some 
of the cases presented in our study illustrate the 
“diagnostic odyssey” faced by the families, with a 
conclusive diagnosis being reached only after the 
cytogenetic evaluation was performed. Our study 
reinforces the idea that the effort to improve the 
capacity to perform molecular cytogenetic studies 
in a public hospital brings benefits to patients, 
relatives and genetic counselors. It also contributes 
to the continuing education of cytogeneticists and 
to the knowledge of chromosomal rearrangements 
associated with genomic disorders.
Acknowledgements
This study was supported by the CNPq/Brazil grant 
number 402012/2010-0, CNPq/Brazil 214906/2012-
4, INCT-INAGEMP 573993/2008-4 and FIPE-HCPA 
GPPG/10-560. The authors appreciate the technical 
assistance and contributions from colleagues from 




1. Schinzel A, Riegel M, Baumer A. 
Microdeletion syndromes. In: Nature 
Encyclopedia of Human Genome. 
London: Macmillan Publishers; New 
York: Nature Publishing Group; 2003. 
p. 950-4.
2. Schmickel RD. Contiguous gene 
syndromes: a component of 




3. Vissers LE, Stankiewicz P. 
Microdeletion and microduplication 




4. Pinkel D, Segraves R, Sudar D, 
Clark S, Poole I, Kowbel D, et al. 
High resolution analysis of DNA copy 
number variation using comparative 
genomic hybridization to microarrays. 
Nat Genet. 1998;20(2):207-11. 
http://dx.doi.org/10.1038/2524. 
PMid:9771718
5. Solinas-Toldo S, Lampel S, 
Stilgenbauer S, Nickolenko J, Benner 
A, Döhner H, et al. Matrix-based 
comparative genomic hybridization: 
biochips to screen for genomic 





6. Iafrate AJ, Feuk L, Rivera MN, 
Listewnik ML, Donahoe PK, Qi Y, et al. 
Detection of large-scale variation 
in the human genome. Nat Genet. 
2004;36(9):949-51. http://dx.doi.
org/10.1038/ng1416. PMid:15286789
7. Redon R, Ishikawa S, Fitch KR, Feuk 
L, Perry GH, Andrews TD, et al. Global 




8. Lupski JR, Stankiewicz P. 
Genomic disorders: molecular 
mechanisms for rearrangements 




9. Girirajan S. Genomic disorders: 
complexity at multiple levels. Genome 
Med. 2013;5(5):43. PMid:23731576.
10. Shaffer LG, Bejjani BA, Torchia B, 
Kirkpatrick S, Coppinger J, Ballif BC. 
The identification of microdeletion 
syndromes and other chromosome 
abnormalities: cytogenetic methods 
of the past, new technologies for the 




11. Pinkel D, Straume T, Gray JW. 
Cytogenetic analysis using 
quantitative, high-sensitivity, 
fluorescence hybridization. Proc Natl 
Acad Sci USA. 1986;83(9):2934-
8. http://dx.doi.org/10.1073/
pnas.83.9.2934. PMid:3458254
12. Shaffer LG, McGowan-Jordan J, 
Schmid M, editors. ISCN 2013: An 
http://seer.ufrgs.br/hcpa Clin Biomed Res 2014;34(4) 365
Molecular cytogenetic evaluation of microdeletions
International System for Human 
Cytogenetic Nomenclature. Basel: 
Karger; 2013.
13. Fernandes MS, Ashton-Prolla P, Matte 
U, Meurer L, Osvaldt A, Bittelbrunn 
AC, et al. A Normativa do Hospital 
de Clínicas de Porto Alegre para 
o armazenamento e utilização de 
materiais biológicos humanos e 
informações associadas em pesquisa: 
uma proposta interdisciplinar. Rev 
HCPA. 2010;30(2):169-79.
14. Schinzel A, Riegel M, Baumer A, 
Superti-Furga A, Moreira LM, Santo 
LD, et al. Long-term follow-up of 
four patients with Langer-Giedion 
syndrome: clinical course and 




15. Jehee FS, Takamori JT, Medeiros 
PF, Pordeus AC, Latini FR, Bertola 
DR, et al. Using a combination of 
MLPA kits to detect chromosomal 
imbalances in patients with multiple 
congenital anomalies and mental 
retardation is a valuable choice 




16. Gillum RF. Epidemiology of congenital 
heart disease in the United States. 
Am Heart J. 1994;127(4 Pt 1):919-
27. http://dx.doi.org/10.1016/0002-
8703(94)90562-2. PMid:8154432
17. Hoffman JI, Kaplan S. The incidence 
of congenital heart disease. J Am 
Coll Cardiol. 2002;39(12):1890-900. 
http://dx.doi.org/10.1016/S0735-
1097(02)01886-7. PMid:12084585
18. Riegel M. Human molecular 
cytogenetics: From cells to 




19. Emy Dorfman L, Leite JC, Giugliani 
R, Riegel M. Microarray-based 
comparative genomic hybridization 
analysis in neonates with congenital 
anomalies: detection of chromosomal 
imbalances. J Pediatr (Rio J). 
2015;91(1):59-67. http://dx.doi.
org/10.1016/j.jped.2014.05.007. 
PMid:25203518
Received: 16/09/2014 
Accepted: 12/10/2014
